The Phase III GLOW trial analysed zolbetuximab plus CAPOX to treat Claudin 18.2 positive, HER2-negative, locally advanced, unresectable or metastatic gastric and gastroesophageal junction cancers. Credit: Kwz~commonswiki / commons.wikimedia.org.

Astellas Pharma has reported that the Phase III GLOW clinical trial of zolbetuximab plus CAPOX as a first-line therapy to treat Claudin 18.2 (CLDN18.2)-positive, HER2-negative, locally advanced, unresectable or metastatic gastric and gastroesophageal junction (GEJ) cancers met the primary endpoint.

The international, double-blind, multicentre, randomised trial was designed to analyse the safety and efficacy of zolbetuximab a versus placebo, along with CAPOX. 

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

According to the positive topline data, the trial met the primary endpoint demonstrating statistically significant progression-free survival (PFS) in zolbetuximab plus CAPOX treated subjects, versus a placebo plus CAPOX. 

A statistically significant overall survival (OS), meeting a crucial secondary endpoint, was seen in zolbetuximab-treated patients versus a placebo. 

Nausea and vomiting were reported to be the most prevalent treatment-emergent adverse events (TEAEs) in the trial.

See Also:

An investigational monoclonal antibody, Zolbetuximab works by attaching to CLDN18.2 seen on the cancer cell surface of gastric epithelial cells.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

A combination chemotherapy regimen, CAPOX comprises capecitabine and oxaliplatin.

Astellas Development Therapeutic Areas senior vice-president and head Ahsan Arozullah said: “We are extremely pleased to share positive topline results from GLOW following the positive SPOTLIGHT readout last month. 

“This further confirms the potential role of zolbetuximab in gastric cancer treatment, an important milestone in our gastric cancer development programme. 

“We intend to discuss these results with regulatory authorities as we continue to develop zolbetuximab for the first-line treatment of patients with locally advanced, unresectable or metastatic gastric and GEJ cancer.”

This study, along with the Phase III SPOTLIGHT trial of zolbetuximab plus oxaliplatin, leucovorin and fluorouracil (mFOLFOX6), was carried out to offer foundational data for filing submissions to the regulatory authorities in the US, Europe, and Asia, among others. 

In September this year, the company reported topline data from the Phase III MOONLIGHT 3 trial of fezolinetant for severe vasomotor symptoms linked to menopause in women in mainland China.